Nektar Therapeutics has announced plans to restructure, reducing its annual spending by $65 million. As part of this initiative, the company will fire 200 full-time workers, comprising nearly one-quarter of its workforce. In its press announcement, reducing costs and reworking its organizational structure will “allow the company to accelerate the development of its proprietary pipeline, and improve innovation, focus, and accountability across the enterprise.” Nektar develops PEGylate...